Loading
A phase 2 trial of Quizartinib in acute myeloid leukaemia, run by Daiichi Sankyo, now recruiting.
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission is a phase 2 interventional study registered as NCT06824168 by Daiichi Sankyo, with 130 participants planned, started 2025-07-18 and due to reach its primary completion in 2028-06-06. Interventions recorded: Quizartinib High Dose and Quizartinib Low Dose.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Quizartinib, Daiichi Sankyo, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Daiichi Sankyo, Small-molecule kinase inhibitors and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Shares Daiichi Sankyo and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/